| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 5 Aug 2025 | 21 Jul 2025 |
| Alembic Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2025 ,inter alia, to consider and approve Unaudited Financial Results of the Company for the quarter ended 30th June, 2025 Please find enclosed the Outcome of Board meeting Please find the updated Contact details of KMP and senior officials pursuant to Reg 30 (5) of SEBI LODR Regulations, 2015. (As per BSE Announcement Dated on 05.08.2025) | ||
| Board Meeting | 6 May 2025 | 18 Apr 2025 |
| Alembic Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/05/2025 inter alia to consider and approve With reference to the captioned matter the exchange is hereby informed that a Meeting of Board of Directors of the Company will be held on Tuesday 6th May 2025 Please find attached herewith the Financial Results for the quarter and Financial Year ended 31st March, 2025 Outcome of Board Meeting (As Per BSE Announcement Dated on 05.05.2025) | ||
| Board Meeting | 3 Feb 2025 | 22 Jan 2025 |
| ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2025 inter alia to consider and approve Unaudited Financial Results for the quarter and nine months ended 31st December 2024 Please find the outcome of the meeting. (As per BSE Announcement Dated on 03/02/2025) | ||
| Board Meeting | 7 Nov 2024 | 18 Oct 2024 |
| ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2024 inter alia to consider and approve Unaudited Financial Results of the Company for the quarter and half year ended 30th September 2024 The exchange is hereby informed that the Board of Directors in their Meeting held today has approved the Unaudited Financial Results for the Quarter and Half Year ended September, 2024. (As Per BSE Announcement Dated on 07.11.2024) | ||
The report closes the regulator’s inspection held between May 26 and May 31, 2025, confirming that the manufacturing units met compliance standards.
According to market research firm IQVIA, the US market for this formulation is estimated at around $94 million for the 12 months ending June 2025.
Alembic’s version is a generic substitute for Tegretol-XR, a medicine originally developed by Novartis.
The total value of the deal stands at around $12 million. The company expects to close the transaction within the next month.
Alembic Pharmaceuticals shares have gained 10% in the last year, dipped 2.8% in the year-to-date, and gained 2.3% in the previous month.
EBITDA was up 9% at ₹286 crore, with EBITDA margin at 16% of total sales, reflecting operating efficiency.
The approved product is the generic equivalent of Tegretol Tablets 200 mg, which was initially developed by Novartis Pharmaceuticals Corporation.
This approval bolsters Alembic's portfolio in the United States market and reinforces its presence in injectable segment
Following an inspection carried out from Nov 14-22 2024, the facility was cited as being ‘VAI’ (Voluntary Action Indicated).
EBITDA margin came in at 15.4% in the quarter under review as compared to 16.30% in the previous corresponding period.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
